Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

M. J. Nijland, Hanneke; Ruslami, Rovina; E. Stalenhoef, Janneke; Juwita Nelwan, Erni; Alisjahbana, Bachti; Nelwan, R.H.H.; van der Ven, André; Danusantoso, Halim; E. Aarnoutse, Rob; van Crevel, Reinout

doi:10.1086/507543

Public

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Published in Clinical Infectious Diseases • Sep 5, 2006

Authors:

Hanneke M. J. Nijland

Rovina Ruslami

Janneke E. Stalenhoef

Abstract

BACKGROUND: Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB) and is associated with a slower response to TB treatment and a higher mortality rate. Because lower concentrations of anti-TB drugs may be a contributing factor, we compared the pharmacokinetics of rifampicin in patients ...

Subject

Medicine

Rifampicin

Tuberculosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!